Table 3.
| a: Univariate Cox Analysis | ||||||
|---|---|---|---|---|---|---|
| Category | LC (univariate) | DFI (univariate) | OS (univariate) | |||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age at diag. (continuous) | 1.02 (0.96 – 1.10) | 0.49 | 0.99 (0.95 – 1.03) | 0.66 | 1.05 (1.00 – 1.11) | 0.08 |
| Year of Diagnosis | ||||||
| ≤2010 | 1.00 (0.25 – 3.77) | 1.00 | 1.16 (0.46 – 2.69) | 0.74 | 1.46 (0.57 – 3.72) | 0.43 |
| >2010⋆ | 1 | 1 | 1 | |||
| Tumor size (cm) | ||||||
| Continuous | 0.72 (1.15 – 1.39) | 0.20 | 0.89 (0.66 – 1.13) | 0.36 | 0.97 (0.70 – 1.26) | 0.85 |
| FIGO stage (primary) | ||||||
| III – IV | 1.75 (0.37 – 6.65) | 0.45 | 1.31 (0.47 – 3.17) | 0.58 | 1.11 (0.38 – 2.87) | 0.83 |
| I – II⋆ | 1 | 1 | 1 | |||
| Grade | ||||||
| 3 | 0.36 (0.05 – 1.68) | 0.20 | 1.28 (0.37 – 3.18) | 0.89 | 3.71 (1.19 – 14.33) | 0.02 |
| 2 | 0.37 (0.05 – 1.71) | 0.21 | 1.28 (0.46 – 3.64) | 0.64 | 1.05 (0.28 – 4.28) | 0.94 |
| 1⋆ | 1 | 1 | 1 | |||
| Lymphovascular invasion | ||||||
| Yes | 0.13 (0.01 – 0.74) | 0.02 | 0.38 (0.14 – 0.94) | 0.03 | 2.29 (0.84 – 6.81) | 0.10 |
| Lymph node involvement | ||||||
| Yes | 0.35 (0.02 – 1.94) | 0.26 | 1.35 (0.52 – 3.17) | 0.51 | 1.03 (0.36 – 2.62) | 0.95 |
| Chemotherapy at initial diagnosis⍰ | ||||||
| Yes | 1.21 (0.18 – 5.05) | 0.81 | 2.59 (0.98 – 6.16) | 0.06 | 0.79 (0.19 – 2.39) | 0.71 |
| Any chemotherapy at recurrence | ||||||
| Yes | 0.12 (0.01–0.67) | 0.01 | 1.15 (0.51—2.67) | 0.72 | 0.51 (0.18— 1.35) | 0.18 |
| Concurrent chemotherapy at recurrence | ||||||
| Yes | 0.16 (0.01—0.87) | 0.03 | 0.93 (0.40—2.13) | 0.87 | 0.28 (0.08—0.82) | 0.02 |
| Prior radiation therapy | ||||||
| Yes | 2.51 (0.66 – 10.21) | 0.17 | 1.61 (0.67 – 3.71) | 0.28 | 2.97 (1.16 – 7.91) | 0.03 |
| BT imaging status | ||||||
| MR-guided ISBT | -- | -- | 0.44 (0.13 – 1.18) | 0.11 | 1.13 (0.36 – 3.09) | 0.82 |
| CT-guided ISBT⋆ | 1 | 1 | 1 | |||
| BT dose (EQD2) (continuous) | 0.99 (0.92 – 1.04) | 0.61 | 1.00 (0.97 – 1.03) | 0.93 | 1.01 (0.97 – 1.04) | 0.65 |
| Cum. dose (EQD2) | ||||||
| Continuous | 1.02 (0.96 – 1.08) | 0.42 | 1.05 (1.00 – 1.08) | 0.03 | 1.02 (0.98 – 1.06) | 0.28 |
| ≤70.0 Gy | 2.25 (0.55 – 8.53) | 0.24 | 0.59 (0.19 – 1.51) | 0.29 | 0.40 (0.09 – 1.21) | 0.11 |
| >70.0 Gy⋆ | 1 | 1 | 1 | |||
| Cum. D90 (EQD2) | ||||||
| Continuous | 1.02 (0.97 – 1.08) | 0.35 | 1.04 (1.01 – 1.07) | 0.01 | 1.03 (0.99 – 1.06) | 0.15 |
| ≤70.0 Gy | 0.56 (0.08 – 2.33) | 0.45 | 0.34 (0.10 – 0.92) | 0.03 | 0.47 (0.14 – 1.30) | 0.15 |
| >70.0 Gy⋆ | 1 | 1 | 1 | |||
| 2-year K-M rate | 84% | 70% | 85% | |||
| 3-year K-M rate | 84% | 60% | 72% | |||
| 5-year K-M rate | 79% | 46% | 53% | |||
| b: Multivariable Cox Analysis | ||
|---|---|---|
| LC (adjusted) | ||
| HR (95% CI) | p-value | |
| Lymphovascular invasion | 0.08 (0.01 – 0.45) | 0.001 |
| Any chemotherapy at recurrence | 0.07 (0.003 – 0.40) | 0.001 |
| DFI (adjusted) | ||
| MR-based ISBT | 0.62 (0.16 – 1.92) | 0.42 |
| Lymphovascular invasion | 0.42 (0.13 – 1.92) | 0.09 |
| Cum. D90 (EQD2)⍰ | 1.05 (1.01 – 1.09) | 0.01 |
| OS (adjusted) | ||
| HR (95% CI) | p-value | |
| MR-based ISBT | 0.56 (0.16 – 1.89) | 0.36 |
| Tumor grade** | 3.57 (1.25 – 11.36) | 0.02 |
| Concurrent chemotherapy at recurrence | 0.59 (0.15 – 1.88) | 0.38 |
⋆
Referent group; Diag, Diagnosis; BT, Brachytherapy; ISBT, Interstitial brachytherapy; Adenoca, Adenocarcinoma; Cum, Cumulative;
⍰
Chemotherapy for initial disease
**
compared grade 3 versus grade 1–2 as referent;
⍰
≤70 vs >70 Gy